Michael Lipp, PhD

Michael Lipp co-founded Decoy Therapeutics and serves as Chief Technology Officer. He has more than two decades of experience in pharmaceutical development and drug delivery, with roles at Nocion Therapeutics, Acorda Therapeutics, Civitas Therapeutics, Pulmatrix, and Alkermes, much of it focused on inhaled and pulmonary delivery of therapeutics. He was previously a post-doctoral associate and research affiliate in the Langer Laboratory at MIT.